



## OFF-TARGET BINDING

Off-target antibody binding is common and can cause serious adverse events




**62%**  
of Preclinical Failures are due to Off-target Safety




**25%** of MABs are polyspecific

Off-target binding is the leading cause of preclinical drug failures and can cause serious side effects including death.


## Many MABs have off-target binding




- Multi-billion dollar market
- FDA black box warning



- \$500M sales annually
- Used for multiple diseases




- Company purchased for > \$1B
- Off-target is widely expressed




- Immune checkpoint off-target
- Patient deaths in clinical trials

## THE MEMBRANE PROTEOME ARRAY


De-risk preclinical development by identifying your antibody's target and off-target interactions on the Membrane Proteome Array (MPA).



6,000  
Native human membrane proteins



Measure binding  
In unfixed cells by  
flow cytometry



Specificity profile  
across membrane proteome

## OPTIMIZED FOR RAPID 4-WEEK TURNAROUND

### What proteins are in the MPA?

The MPA is the largest library of its kind and contains 94% of the human membrane proteome. All protein classes are represented, including nearly all GPCRs, ion channels, transporters, single-pass, multi-pass, and GPI-anchored proteins.

### Why is the MPA so successful?

- Largest human membrane protein library
- Physiologically relevant screening conditions using unfixed cells
- High-sensitivity flow cytometry
- Optimized and expression-validated targets

# Integral Molecular's Membrane Protein Solutions

Integral Molecular offers innovative solutions for antibody discovery against challenging membrane protein targets, including GPCRs, ion channels, transporters, viral envelopes and immuno-oncology targets. With 15+ years experience working with the most complex proteins, Integral Molecular enables the isolation, characterization and engineering of monoclonal antibodies against otherwise intractable targets.




*MPS Antibody Discovery*




*Lipoparticles*



*Epitope Mapping*



*Membrane Proteome Array*



*Vaccine Development*


## MPS Antibody Discovery



We harness proprietary technologies, including Lipoparticles, DNA immunization, and B-cell cloning, and use divergent species to overcome the challenges of working with membrane proteins and deliver lead MABs

- >95% success in isolating MABs against GPCRs, ion channels, transporters, and I-O targets
- Hundreds of diverse and functional (antagonist/agonist) MABs

## Shotgun Mutagenesis Epitope Mapping



Detailed epitope mapping using comprehensive alanine scanning across the native protein informs antibody mechanism of action and strengthens intellectual property

- >95% success rate for delivering high-resolution conformational epitopes
- 1,000+ epitopes mapped on secreted, cytoplasmic, and membrane protein targets


## Lipoparticles



Lipoparticles are virus-like particles that concentrate membrane proteins in their native conformation for better immunization, phage panning, and screening

- 10-100x concentrated membrane proteins (50-200 pmol/mg)
- Conformationally correct

## Membrane Proteome Array



The Membrane Proteome Array is used to profile MAB specificity and evaluate off-target safety by utilizing 6,000 human membrane proteins expressed in live cells

- Expression in live human cells and screening in unfixed cell-based assays
- 4-week turn-around, including validation by flow cytometry